# EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Study · id `cardio:ct-nct04509674` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04509674](<https://clinicaltrials.gov/study/NCT04509674>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04509674

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6522 participants.

## Technical summary

Registry record NCT04509674. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-16 (actual); primary completion 2023-11-05 (actual). Results posted on 2025-01-07.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 6522 participants (enrolled count; ClinicalTrials.gov record NCT04509674, source copy `cardio:ctgov-nct04509674-2025-01-07`, retrieved 2026-10-26)
- Started: 2020-12-16 (actual) (ClinicalTrials.gov record NCT04509674, source copy `cardio:ctgov-nct04509674-2025-01-07`, retrieved 2026-10-26)
- Primary completion: 2023-11-05 (actual) (ClinicalTrials.gov record NCT04509674, source copy `cardio:ctgov-nct04509674-2025-01-07`, retrieved 2026-10-26)
- Completion: 2023-11-05 (actual) (ClinicalTrials.gov record NCT04509674, source copy `cardio:ctgov-nct04509674-2025-01-07`, retrieved 2026-10-26)
- Results first posted: 2025-01-07 (ClinicalTrials.gov record NCT04509674, source copy `cardio:ctgov-nct04509674-2025-01-07`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; China; Denmark; France; Germany; Hungary; India; Israel; Japan; Netherlands; Poland; Romania; Russia; Serbia; South Korea; Spain; Ukraine (ClinicalTrials.gov record NCT04509674, source copy `cardio:ctgov-nct04509674-2025-01-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04509674-2025-01-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
- Condition: Myocardial Infarction
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Empagliflozin after Acute Myocardial Infarction (`cardio:pubmed-38587237`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial (`cardio:pubmed-38581389`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction (`cardio:pubmed-38588929`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 5095dba731800a7827c8a40824c700817c5fa56a869f9620948624416077891b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
